

Placebo and Nocebo Publications October 2022

1. Amanzio, M., Cipriani, G. E., & Mitsikostas, D. D. (2022). The nocebo phenomenon in the COVID-19 pandemic: a nocebodemic effect. *Expert Rev Clin Pharmacol*, 1-6. doi:10.1080/17512433.2022.2142115
<https://www.ncbi.nlm.nih.gov/pubmed/36305792>
2. Chin, Y. H., Ng, C. H., Chew, N. W., Kong, G., Lim, W. H., Tan, D. J. H., Chan, K. E., Tang, A., Huang, D. Q., Chan, M. Y., Figtree, G., Wang, J. W., Shabbir, A., Khoo, C. M., Wong, V. W., Young, D. Y., Siddiqui, M. S., Nouredin, M., Sanyal, A., Cummings, D. E., Syn, N. & Muthiah, M. D. (2022). The placebo response rate and nocebo events in obesity pharmacological trials. A systematic review and meta-analysis. *EClinicalMedicine*, 54, 101685. doi:10.1016/j.eclinm.2022.101685
<https://www.ncbi.nlm.nih.gov/pubmed/36193169>
3. Darbellay, C., Magnin, S., Haidar Ahmad, A., Wolff, A., Serratrice, J., & Coen, M. (2022). [Healing communication: Therapeutic communication in internal medicine]. *Rev Med Suisse*, 18(801), 2026-2029. doi:10.53738/REVMED.2022.18.801.2026
<https://www.ncbi.nlm.nih.gov/pubmed/36314093>
4. Fraguas, D., Díaz-Caneja, C. M., Pina-Camacho, L., Umbricht, D., & Arango, C. (2022). Correction to: Predictors of Placebo Response in Pharmacological Clinical Trials of Negative Symptoms in Schizophrenia: A Meta-regression Analysis. *Schizophr Bull*. doi:10.1093/schbul/sbac172
<https://www.ncbi.nlm.nih.gov/pubmed/36315443>
5. Gerke, L., Ladwig, S., Pauls, F., Trachsel, M., Harter, M., & Nestoriuc, Y. (2022). Optimized Informed Consent for Psychotherapy: Protocol for a Randomized Controlled Trial. *JMIR Res Protoc*, 11(9), e39843. doi:10.2196/39843
<https://www.ncbi.nlm.nih.gov/pubmed/36178713>
6. Hohenschurz-Schmidt, D., Draper-Rodi, J., Vase, L., Scott, W., McGregor, A., Soliman, N., MacMillan, A., Olivier, A., Cherian, C. A., Corcoran, D., Abbey, H., Freigang, S., Chan, J., Phalip, J., Sorensen, L. N., Delafin, M., Baptista, M., Medforth, N. R., Ruffini, N., Andresen, S. S., Ytier, S., Ali, D., Hobday, H., Ngurah Agung Adhiyoga Santosa, A. A., Vollert, J. & Rice, A. S. C. (2022). Blinding and sham control methods in trials of physical, psychological, and self-management interventions for pain (article II): a meta-analysis relating methods to trial results. *Pain*. doi:10.1097/j.pain.0000000000002730
<https://www.ncbi.nlm.nih.gov/pubmed/36271798>

7. Iwama, Y., Takamoto, K., Hibi, D., Nishimaru, H., Matsumoto, J., Setogawa, T., & Nishijo, H. (2022). Young female participants show blunted placebo effects associated with blunted responses to a cue predicting a safe stimulus in the right dorsolateral prefrontal cortex. *Front Neurosci*, 16, 1001177. doi:10.3389/fnins.2022.1001177
<https://www.ncbi.nlm.nih.gov/pubmed/36263366>
8. Kirsch, D. E., Le, V., Kosted, R., Fromme, K., & Lippard, E. T. C. (2022). Neural underpinnings of expecting alcohol: Placebo alcohol administration alters nucleus accumbens resting state functional connectivity. *Behav Brain Res*, 437, 114148. doi:10.1016/j.bbr.2022.114148
<https://www.ncbi.nlm.nih.gov/pubmed/36206822>
9. Klosowska, J., Bajcar, E. A., Bieniek, H., Braczyk, J., Joshanloo, M., Mattarozzi, K., Bagnis, A., Ponten, M., Lalouni, M., Geers, A. L., Clemens, K. S., Park, J., Choi, G., Choi, Y. K., Jung, W., Son, E., Yoon, H. Y. & Babel, P. (2022). Development and cross-national investigation of a model explaining participation in WHO-recommended and placebo behaviours to prevent COVID-19 infection. *Sci Rep*, 12(1), 17704. doi:10.1038/s41598-022-17303-y
<https://www.ncbi.nlm.nih.gov/pubmed/36271008>
10. Lin Tay, P. W., Ng, C. H., Lin, S. Y., Chin, Y. H., Xiao, J., Lim, W. H., Lim, S. Y., Fu, C. E., Chan, K. E., Quek, J., Hao Tan, D. J., Chew, N., Syn, N., Keitoku, T., Tamaki, N., Siddiqui, M. S., Nouredin, M., Muthiah, M., Huang, D. Q. & Loomba, R. (2022). Placebo Adverse Events in Non-Alcoholic Steatohepatitis Clinical Trials. A Pooled Analysis of 2,944 Participants. *Am J Gastroenterol*. doi:10.14309/ajg.0000000000002042
<https://www.ncbi.nlm.nih.gov/pubmed/36191268>
11. Nedrud, M. A., Chaudhry, M., Middleton, M. S., Moylan, C. A., Lerebours, R., Luo, S., Farjat, A., Guy, C., Loomba, R., Abdelmalek, M. F., Sirlin, C. B. & Bashir, M. R. (2022). MRI Quantification of Placebo Effect in Nonalcoholic Steatohepatitis Clinical Trials. *Radiology*, 220743. doi:10.1148/radiol.220743
<https://www.ncbi.nlm.nih.gov/pubmed/36318027>
12. Nissen, S. E. (2022). When Is a Placebo Not a Placebo. *JAMA Cardiol*. doi:10.1001/jamacardio.2022.3698
<https://www.ncbi.nlm.nih.gov/pubmed/36287549>
13. Nohr, A. K., Forsingdal, A., Moltke, I., Howes, O. D., Vitezic, M., Albrechtsen, A., & Dalby, M. (2022). Polygenic heterogeneity in antidepressant treatment and placebo response. *Transl Psychiatry*, 12(1), 456. doi:10.1038/s41398-022-02221-4
<https://www.ncbi.nlm.nih.gov/pubmed/36309483>

14. O'Riordan, S. F., Bishop, D. J., Halson, S. L., & Broatch, J. R. (2022). Compression-induced improvements in post-exercise recovery are associated with enhanced blood flow, and are not due to the placebo effect. *Sci Rep*, 12(1), 16762. doi:10.1038/s41598-022-21029-2
<https://www.ncbi.nlm.nih.gov/pubmed/36202885>
15. Sharma, T., Ma, C., Sedano, R., Hanzel, J., McDonald, C., Hogan, M., Kochhar, G. S., Narula, N., Peyrin-Biroulet, L., Danese, S., MacDonald, J. K. & Jairath, V. (2022). Placebo response rates in randomized controlled trials for perianal Crohn's disease: A systematic review and meta-analysis. *J Crohns Colitis*. doi:10.1093/ecco-jcc/jjac160
<https://www.ncbi.nlm.nih.gov/pubmed/36271904>
16. Svobodova, M., Jacob, N., Hood, K., Gillies, K., Hale, R., Bostock, J., Bower, P., Edwards, A., Farthing, P., Rawlinson, S., Treweek, S. & Howick, J. (2022). Developing principles for sharing information about potential trial intervention benefits and harms with patients: report of a modified Delphi survey. *Trials*, 23(1), 863. doi:10.1186/s13063-022-06780-1
<https://www.ncbi.nlm.nih.gov/pubmed/36209242>
17. Wager, T. D., & Jung, H. (2022). Unpacking placebo and working memory training effects on cognitive performance. *Proc Natl Acad Sci U S A*, 119(42), e2214268119. doi:10.1073/pnas.2214268119
<https://www.ncbi.nlm.nih.gov/pubmed/36197960>
18. Wen, X., Luo, J., Mai, Y., Li, Y., Cao, Y., Li, Z., Han, S., Fu, Q., Zheng, Q., Ding, C., Zhu, Z. & Li, L. (2022). Placebo Response to Oral Administration in Osteoarthritis Clinical Trials and Its Associated Factors: A Model-Based Meta-analysis. *JAMA Netw Open*, 5(10), e2235060. doi:10.1001/jamanetworkopen.2022.35060
<https://www.ncbi.nlm.nih.gov/pubmed/36215072>
19. Wise, J., Ingrosso, M. R., Ianiro, G., Black, C. J., Ford, A. C., & Lacy, B. E. (2022). Response and Adverse Event Rates with Placebo in Gastroparesis: A Systematic Review and Meta-analysis. *Clin Gastroenterol Hepatol*. doi:10.1016/j.cgh.2022.09.033
<https://www.ncbi.nlm.nih.gov/pubmed/36270614>
20. Yoon, J. H. (2022). A Placebo Effect on MRI Proton Density Fat Fraction in Nonalcoholic Steatohepatitis Trials. *Radiology*, 222295. doi:10.1148/radiol.222295
<https://www.ncbi.nlm.nih.gov/pubmed/36318034>